PMID: 8448753Mar 1, 1993Paper

Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma

Cancer
H W SnyderD Wuest

Abstract

Chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS) is a condition involving thrombocytopenia, microangiopathic hemolytic anemia, and progressive renal dysfunction that develops in 2-10% of patients with a history of malignant neoplasms treated with certain chemotherapeutic agents. Pathogenesis of the disease may depend on the following: (1) generation of endothelial lesions in the kidney microvasculature, resulting from drug toxic effects and/or generation of small soluble circulating immune complexes (CIC), and (2) generation of autoantibodies and/or CIC that trigger aggregation and deposition of platelets around the lesions. Extracorporeal immunoadsorption treatment of plasma (PROSORBA columns, IMRE Corporation, Seattle, WA) to remove immunoglobulin G and CIC was evaluated in 55 patients for the potential to induce significant clinical benefits (increase in platelet count, decrease in hemolysis, stabilization of renal function) and longer survival. Response to therapy was achieved in 25 of 55 patients examined. Response was associated with an estimated 1-year survival rate of 61%, as compared with an estimated survival rate of only 22% in those who did not respond (P = 0.0001). P...Continue Reading

References

Jul 1, 1979·Human Pathology·D L LaffayL J McCormack
Jan 1, 1985·Journal of Cancer Research and Clinical Oncology·J van der MeerJ G Aalders
Jun 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J B LesesneP S Schein
May 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S ChowD C Cattran
Feb 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G L MesserschmidtE Ambinder
May 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E CantrellP S Schein
Feb 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S KorecT M Phillips
Mar 1, 1986·Archives of Internal Medicine·J L GremP P Carbone
Nov 8, 1980·Lancet·K W RumpfF Scheler
Jul 1, 1984·Annals of Internal Medicine·A M JacksonR G Narins
Dec 1, 1984·Archives of Pathology & Laboratory Medicine·A D ProiaH R Silberman
Jan 1, 1983·Cancer Chemotherapy and Pharmacology·D J Perry
Jun 1, 1984·American Journal of Clinical Oncology·T S RavikumarT B Grage
Jul 1, 1984·European Journal of Cancer & Clinical Oncology·U BruntschW M Gallmeier
Dec 15, 1981·Cancer·W T HannaW M Murphy

❮ Previous
Next ❯

Citations

Jan 1, 1992·International Journal of Clinical & Laboratory Research·D Ciavarella
Jan 30, 2004·The American Journal of Medicine·Nicola Zetola-Burneo, Cynthia Brown
Sep 15, 2001·European Journal of Internal Medicine·F RetornazJ Soubeyrand
Feb 6, 1998·Transfusion Science·E J BorghardtK Fenchel
Feb 6, 1998·Transfusion Science·N BraunT Risler
Mar 21, 2000·Transfusion Science·J B Gorlin
Jun 2, 1998·Environmental Toxicology and Pharmacology·J N Dhuley, S R Naik
Jul 1, 2009·Nature Reviews. Nephrology·Vaibhav SahniZiauddin Ahmed
Jul 11, 2000·British Journal of Haematology·G A Rock
Jun 26, 2001·Journal of Clinical Pharmacy and Therapeutics·G ErsozY Batur
Dec 23, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·D BuenoA A Kaplan
Jul 26, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·A A Kaplan
Jan 10, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·G MaticW Ramlow
Aug 8, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Hans von Baeyer
Apr 1, 1997·Japanese Journal of Clinical Oncology·D C WuJ Whang-Peng
Oct 18, 2001·Current Opinion in Hematology·P J MedinaJ N George
May 28, 2014·Thrombosis Research·Marcel Levi
Dec 1, 2009·Critical Care Clinics·Dominique D Benoit, Eric A Hoste
Nov 2, 2004·Obstetrics and Gynecology·Dele A OgunleyeThomas J Herzog
Mar 17, 2009·Best Practice & Research. Clinical Haematology·Marcel Levi
Nov 13, 2001·Mayo Clinic Proceedings·M A Elliott, W L Nichols
Sep 4, 2007·The Lancet Oncology·Jecko Thachil
Jul 7, 2007·The Lancet Oncology·Melanie ZupancicFarheen Shah-Khan
Jan 29, 2011·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Rolf BambauerRalf Schiel
May 7, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Hassan Izzedine, Mark A Perazella
Jan 1, 1996·Transfusion Medicine Reviews·D W Huestis, F S Morrison
Feb 14, 2006·Seminars in Oncology·Nasir ShahabDonald C Doll
Feb 14, 2006·Seminars in Oncology·Maja J A de Jonge, Jaap Verweij
Oct 5, 2013·Journal of Chemotherapy·Frederico LealJosé Barreto C Carvalheira
Apr 1, 1996·Hematology/oncology Clinics of North America·J L Moake, J J Byrnes
Mar 12, 2003·Hematology/oncology Clinics of North America·Chadi Nabhan, Hau C Kwaan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.